AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02509286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;
Study NCT02509286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.
Study NCT02509286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;
Study NCT02509286 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant radiation
Description: 41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
Study NCT02247687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protease inhibitor
Description: Modification in the antiretroviral treatment~•Switch arm for protease inhibitor : intervention switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.
Study NCT02247687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isentress® (raltegravir)
Description: • Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling
Study NCT02247687 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Counseling arm
Description: No change of antiretroviral treatment but only counseling
Study NCT00643305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Building with Motivational Interviewing
Description: Based on the Stages of Change model, participants are provided with feedback related to their current HIV risk and Motivational Interviewing strategies are used to increase motivation to decrease HIV risk behaviors. Participants are also provided with information and training in skills critical for reducing HIV risk
Study NCT00643305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skills Building
Description: Participants are provided with information and training in skills critical for reducing HIV risk.
Study NCT03720548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372993
Description: Administered IV.
Study NCT03720548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study NCT01071876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: 1 capsule in the morning before breakfast
Study NCT01071876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule in the morning before breakfast
Study NCT01559116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Description: low dose + one dose only
Study NCT01559116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: low dose
Study NCT01559116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olodaterol
Description: one dose only
Study NCT01559116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: high dose
Study NCT01559116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching tiotropium+olodaterol FDC
Study NCT01559116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study NCT02496754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH-a
Description: In control group, patients use short term GnRH-a. Patients' serum or follicle fluid will be collected if needed.
Study NCT01470820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy with blue light
Description: The infants were placed in a bassinet with the phototherapy device placed above them. All infants were exposed naked (apart from eye pads and diaper) to continuously phototherapy for 24 hours, interrupted only for feeding and nursing for 30 minutes every three hours. TsB was determined before phototherapy and after 24 hours of treatment. The phototherapy apparatus used was neoBLUE LED phototherapy device (Natus Medical Inc., San Carlos, CA, USA) emitting blue light with an emission peak at 460 nm and a bandwidth of 450-470 nm. The irradiance was measured by use of the neoBLUE LED phototherapy radiometer (Natus Medical Inc.) every 8th hour at the infants head, trunk and knees and the average was calculated. The radiometer measures spectral irradiance in the range 420-500 nm with maximum sensitivity in the spectrum 440-480 nm.
Study NCT01559116 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat
Description: Respimat inhaler
Study NCT04019821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: A type of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
Study NCT04002089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: bupivacaine liposome injectable suspension
Study NCT04002089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 1.3%, 13.3 mg/mL
Study NCT04002089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 1.3%, 13.3 mg/mL
Study NCT01775046 — intervention group
Intervention type: DEVICE
Intervention: DTA patients (Valiant)
Description: Valiant Thoracic Stent Graft Implantation
Study NCT03110679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of autologous bone marrow concentrate
Study NCT03110679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of hyaluronic acid.
Study NCT01559116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study NCT00694044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: 0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days
Study NCT00694044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: 0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days
Study NCT00694044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: 0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days
Study NCT00694044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 21 days
Study NCT04837456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calorie restricted diet and exercise intervention
Description: the calorie restricted diet were prescribed a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement.Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%\[36\]. Participants were guided by a dietitian for adjustments of their caloric intake weekly for six months.Participants performed 1 or 2 sets at a resistance of approximately 65% of their one-repetition maximum, with 8 to 12 repetitions of each exercise; they gradually increased the intensity to 2 to 3 sets at a resistance of approximately 80% of their one-repetition maximum, with 6 to 8 repetitions of each exercise.
Study NCT04837456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: libitum diet and waiting list control group
Description: libitum diet and waiting list control group, participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.
Study NCT04837456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early arthroscopic partial menisectomy group
Description: Early APM group participants received APM with syndrome within 3 to 6 months
Study NCT04837456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed APM group recruit participants with symptoms lasting for more than 6 months
Description: delayed APM group recruit participants with symptoms lasting for more than 6 months
Study NCT04292691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40ml of Ropivacaine 0.5% Injectable Solution
Description: already outlined in the arm/group description
Study NCT04292691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 40ml of Ringer's Lactate
Description: already outlined in the arm/group description
Study NCT01009385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical epidural steroid injection
Description: * After aseptic preparation and skin infiltration with 1% lidocaine~* 20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level~* identification of the epidural space confirmed by injection of contrast medium under fluoroscope~* injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).~* Post-procedure, patients were observed for any adverse effects and followed with a neurological examination
Study NCT03031951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Group
Description: The intervention group will start the lifestyle intervention with a 60-minute nutrition appointment given by a certified dietitian. This meeting is intended to provide a well-balanced personalized diet plan, calculated to create a moderate reduction from \~300 to 500kcal/day according to each participant's energy requirements and preferences. Two additional follow-up appointments are also planned to adjust the individual energy requirements throughout the intervention. Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 60-90 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Weight will be monitored weekly.
Study NCT03697226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical ABI-1968
Description: Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
Study NCT00838162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 75 mg twice daily
Description: TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
Study NCT00838162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 150 mg twice daily
Description: TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
Study NCT01009385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural pressure measurement
Description: * The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.~* Identification of the epidural space and measurement of EP was performed with a closed measurement system.
Study NCT06260176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to healthy labels only
Description: Green labels only for beverages and foods scored as healthy
Study NCT00838162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg twice daily
Description: TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
Study NCT00838162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg once daily
Description: TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
Study NCT00838162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg twice daily
Description: Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
Study NCT00838162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg once daily
Description: Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
Study NCT05696548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered at a dose of 24mg as oral dose, one a day
Study NCT05696548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks
Study NCT06260176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to healthiness information
Description: All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
Study NCT03234309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV
Study NCT06260176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to physical activity equivalents
Description: All beverages and foods labeled with physical activity required to burn their calories
Study NCT06260176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure to sweetened beverage tax messaging
Description: Message reminding consumers to make healthier choices
Study NCT02864745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional electrical stimulation-assisted cycle ergometry
Description: Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry
Study NCT02864745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard rehabilitation
Description: This group will receive standard rehabilitation, which will be monitored, but not protocolised.
Study NCT02532868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0457
Study NCT04590937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet
Study NCT04590937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRESTOR®
Description: Film-coated tablet
Study NCT04590937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenoxin®
Description: Tablet
Study NCT04590937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetfoLiquid GeriaSan®
Description: Oral solution
Study NCT04590937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasix®
Description: Oral solution
Study NCT01271478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: captopril plus placebo
Description: This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
Study NCT01271478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan plus placebo
Description: Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day
Study NCT01271478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan plus Captopril
Description: Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)
Study NCT01271478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group will receive 2 tablets of placebo (starch) twice a day.
Study NCT00518453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Surface antigen inactivated influenza vaccine
Description: 1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
Study NCT02526615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Patients received either placebo, metformin or rosiglitazone
Study NCT02526615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients received either placebo, metformin or rosiglitazone
Study NCT02526615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received either placebo, metformin or rosiglitazone
Study NCT00544128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine, abacavir , ritonavir, atazanavir
Description: Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
Study NCT00544128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine, tenofovir, ritonavir, atazanavir
Description: Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
Study NCT02832804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
Study NCT02832804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
Study NCT02832804 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
Study NCT03808272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HOT AXIOS Stent and Electrocautery- Enhanced Delivery System
Description: The HOT AXIOS Stent and Electrocautery- Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content.
Study NCT01212133 — intervention group
Intervention type: DRUG
Intervention: liraglutide
Description: Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.
Study NCT01306877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEA Hemorrhoid and Prolapse Stapling Set
Description: Surgical device
Study NCT01306877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosurgery Proximate PPH03 Stapling Set
Description: Surgical device
Study NCT04123028 — intervention group
Intervention type: OTHER
Intervention: observatory
Description: observation for 1 year period
Study NCT02948283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02948283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO
Study NCT02948283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02948283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Given PO
Study NCT02948283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life
Description: Ancillary studies
Study NCT02948283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies
Study NCT01915966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardamom, ginger and orange juice gelatin
Description: Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation
Study NCT01915966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Camomile infusion with lemon juice
Description: Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
Study NCT04186689 — intervention group
Intervention type: OTHER
Intervention: Routine Dental Examination
Description: Routine dental examination for the pre-school children Questionnaire for their mothers
Study NCT02003339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional RMIs
Study NCT03000270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impella unloading prior to PPCI
Description: Impella unloading prior to PPCI
Study NCT00890188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THALIDOMIDE and UFUR
Description: T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
Study NCT03825471 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: electrotherapy
Description: Cranial electrotherapy stimulation
Study NCT03825471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrotherapy
Description: Cranial electrotherapy stimulation
Study NCT03825471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opioid Anesthetics
Description: consumption of opioids during general anesthesia
Study NCT03825471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Anesthetics
Description: consumption of opioids during general anesthesia
Study NCT03825471 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: colon cancer surgery
Description: laparoscopic colon cancer surgery